ClinicaliQ Trial Snapshot
- Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) — Recruiting • Phase III • Cardiology / Cardiovascular • NCT07453888.
- What is being tested: Intranasal cenegermin (a recombinant human nerve growth factor) versus vehicle control to assess efficacy and safety in treating non-arteritic anterior ischemic optic neuropathy (NAION), a sudden optic nerve condition causing vision loss.
- Patient eligibility overview: Approximately 272 adult participants with confirmed NAION diagnosis meeting specific eligibility criteria will be randomised in this phase 3, double-masked, multicentre trial across UK healthcare settings.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION. Approximately 272 participants who meet all eligibility criteria will be randomly assigned in a 1:1 ratio to receive either cenegermin treatment (Group 1) or the vehicle control (Group 2).
Eligibility Snapshot
- Key Inclusion Criteria: 1. A clinical diagnosis of unilateral NAION in the study eye with symptom onset within 14 days prior to the planned date for first dose administration. 2. A BCVA score in the study eye of ≥ 15 letters and ≤ 65 letters measured using the ETDRS chart. 3. Sufficiently clear ocular media and adequate pupil dilation to enable assessment of the optic nerve and retina in both eyes. Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.